A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to determine the safety and tolerability of BI 853520
monotherapy by defining the maximum tolerated dose (MTD) and recommending the dose for
further trials in the development of this compound.
Secondary objectives are
- determination of the pharmacokinetic (PK) profile;
- exploratory pharmacodynamic analysis; and
- collection of preliminary data on anti-tumour efficacy.